Highest-materiality recent filing
Rein Therapeutics prices $50M public offering of 50M shares at $1.00/share
Gross proceeds $50M from 50M shares at $1.00; net proceeds ~$46.1M after discounts and expenses.
Rein Therapeutics issues $2.875M in unsecured notes to institutional investors at 20% OID
Issued $2.875M aggregate principal notes for $2.3M net cash (20% original issue discount).
Director Manuel C. Alves Aivado resigns from Rein Therapeutics board effective Feb 16
Manuel C. Alves Aivado, M.D., Ph.D., resigned as board member effective February 16, 2026.
Rein Therapeutics issues $2.5M unsecured promissory note with 20% OID to Funicular Funds
Issued $2.5M principal unsecured promissory note sold for $2M (20% original issue discount) to Funicular Funds, LP.
Rein Therapeutics terminates Yorkville equity facility; $3M drawn, no penalties
Terminated Pre-Paid Advance and Standby Equity Purchase Agreements with Yorkville on Dec 11, 2025.
FDA lifts clinical hold on Rein Therapeutics' Phase 2 trial of LTI-03 for IPF
FDA lifted full clinical hold after Rein's Complete Response submission; agency confirmed all concerns resolved.
Rein Therapeutics receives third $1.0M Pre-Paid Advance from Yorkville at 95% discount
Third Pre-Paid Advance of $1.0M on Oct 23, 2025; net proceeds $0.95M; total potential up to $6.0M.
Rein Therapeutics receives EMA authorization to begin Phase 2 trial of LTI-03 for IPF
European Medicines Agency approved Phase 2 RENEW trial at clinical sites in Germany and Poland.
FDA confirmed MCH/H findings in GLP rat studies are not dose-limiting for proposed 24-week LTI-03 protocol at doses up to 10 mg/day in IPF patients.
Rein Therapeutics secures up to $6.0M in prepaid advances from Yorkville; second $1.0M tranche drawn
Entered Pre-Paid Advance Agreement with Yorkville for up to $6.0M over 12 months; initial $1.0M advance closed July 29, 2025.
Rein Therapeutics gets UK MHRA nod for Phase 2 IPF trial of LTI-03
UK MHRA authorized Phase 2 'RENEW' trial of LTI-03 for idiopathic pulmonary fibrosis (IPF).
Rein Therapeutics enters up to $21M financing with Yorkville via PPA and SEPA
Pre-Paid Advance Agreement: up to $6M; initial $1M advance at 95% net ($0.95M); 8% annual interest rising to 18% on default.
Rein Therapeutics stockholders elect director Fairey, approve say-on-pay
William C. Fairey elected as Class II director for three-year term expiring 2028; 7,661,847 for, 1,621,599 withheld.
FDA placed Phase 2 RENEW trial of LTI-03 on clinical hold on July 8, 2025 via formal letter.
Rein Therapeutics adjourns annual meeting to July 23 due to lack of quorum
Annual Meeting originally set for June 24, 2025, adjourned after quorum not achieved.
Rein Therapeutics pauses US enrollment in Phase 2 RENEW trial due to FDA clinical hold
FDA placed clinical hold on Phase 2 RENEW trial of LTI-03 on June 10, 2025; US enrollment and dosing paused.
Rein Therapeutics Q1 net loss $5.5M; Phase 2 IPF trial initiated
Net loss $5.5M ($0.25/shr) vs $7.1M ($0.86/shr) year ago; revenue not reported.
Rein Therapeutics raises ~$5.05M via warrant exercises, exchanges, and private placement
Holders exercise 2023 and 2024 warrants for 902,929 shares at reduced price of $1.60 per share.
Rein Therapeutics auditor Marcum resigns, CBIZ appointed; going concern noted
Marcum LLP resigned as independent auditor on April 16, 2025; CBIZ CPAs P.C. engaged by Audit Committee.
Rein Therapeutics (formerly Aileron) changes name to Rein Therapeutics, new ticker RNTX
Name change from Aileron Therapeutics to Rein Therapeutics effective January 10, 2025 at 4:00 p.m. Eastern Time.
Aileron Therapeutics reports Q3 net loss of $5.8M; Phase 1b LTI-03 shows positive biomarker data
Net loss of $5.8M ($0.27 per share) compared to $1.8M ($0.40) in Q3 2023; R&D expenses increased to $3.7M from $0.1M.
Aileron Therapeutics 2024 annual meeting: re-elects directors, ratifies auditor
Re-elected Brian Windsor, Ph.D. and Alan A. Musso as Class I directors (7.8M for, ~24k withheld each, 3.4M broker non-votes).
Aileron Q2 2024 net loss $8.9M; positive Phase 1b data for LTI-03 in IPF
Net loss of $8.9M ($0.45 per share) vs $1.8M in Q2 2023; R&D expenses surged to $3.7M from $0.2M.
Aileron Therapeutics enters into ATM equity distribution agreement for up to $50M with Citizens JMP
New Equity Distribution Agreement with Citizens JMP Securities for at-the-market sales of common stock up to $50M.
Aileron sets 2024 annual meeting for Aug 20; shareholder proposals due June 15
Annual meeting date changed to August 20, 2024, more than 30 days from last year's anniversary.
Aileron Therapeutics appoints Timothy Cunningham as interim CFO after Charles Garner departure
Charles Garner departed as CFO on May 15, 2024; Timothy Cunningham appointed interim CFO effective May 16, 2024.
Aileron posts Q1 net loss of $7.1M; positive Phase 1b data for LTI-03 in IPF
Q1 net loss $7.1M ($0.86/share) vs $4.8M ($1.05) in Q1 2023; R&D expenses rose to $3.5M from $1.8M.
Aileron reports positive LTI-03 Phase 1b Cohort 1 IPF data; cash $12.0M
7 of 8 biomarkers showed positive trend; 3 statistically significant: GAL-7 (p=0.0014), TSLP (p=0.0223), Col-1α1 (p=0.0489).
Aileron Therapeutics prices ~$20M registered direct offering of stock and warrants
4,273,505 shares and accompanying warrants sold at combined $4.68/unit; gross proceeds ~$20M, net ~$17.9M.
the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Timothy M. Cunningham, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of May 16, 2024.
Mr. Garner's departure from the Company on May 15, 2024.
Max materiality 0.85 · Median 0.65 · Most common event other_material